Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the completion of its acquisition of Clario Holdings, Inc., a leading provider of endpoint data ...

Scientific services company Thermo Fisher agreed to buy Clario in October for $8.88 billion in cash plus $125 million in January 2027, and then up to $400 million based on the business's performance ...

Thermo Fisher Scientific, already a big player in providing services to the biopharmaceutical industry, is adding to its technology capabilities with the $9 billion acquisition of clinical trial ...

PHILADELPHIA, March 17, 2025 /PRNewswire/ -- Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have acquired NeuroRx, a leader in imaging ...

Clinical trial tech company Clario has sealed its second acquisition in a week, doubling down further on neuroscience by picking up imaging specialist NeuroRx. NeuroRx founder and CEO Douglas Arnold, ...

Drug research is changing and there are opportunities for growth, says Christopher Fikry, the new CEO of clinical trial tech firm Clario. Fikry, who Clario named as its new chief last month, shared ...

Clario's third annual ESG report for the calendar year 2023 highlights advancements in responsible artificial intelligence (AI), employee program investments, and ambitious science-based ...

The ISO 27001 certification validates Clario's systematic and comprehensive approach to information security management practices and recognizes the Company's strong commitment to protecting sensitive ...